Target intelligence / Profile preview

Candida albicans beta-1,2-mannan (Beta-mannan)

Target
Beta-mannan
Molecular classification
Polysaccharide, Glycan, Antigen, Pathogen-associated molecular pattern (PAMP)
01

Overview

Candida albicans beta-1,2-mannan is a unique polysaccharide component of the outermost layer of the Candida cell wall, specifically characterized by its beta-1,2-linked mannosyl residues. It serves as a critical pathogen-associated molecular pattern (PAMP) that is recognized by the host's innate immune system through receptors such as Galectin-3 and TLR4, playing a dual role in both triggering pro-inflammatory responses and facilitating the fungus's escape from immune detection. In clinical practice, beta-mannan is a primary diagnostic biomarker used in the Platelia Candida Ag assay to detect invasive candidiasis in immunocompromised patients. Because beta-1,2-linkages are absent in human glycans, this molecule represents a highly specific target for the development of antifungal immunotherapies, including monoclonal antibodies and glycoconjugate vaccines intended to neutralize the pathogen and enhance opsonization. Research indicates that antibodies specifically targeting these beta-mannan epitopes can confer passive protection against systemic infection, making it a focal point for novel therapeutic strategies against multi-drug resistant Candida species.

Other names
Beta-1,2-linked mannosyl residuesCandida mannanPhospholipomannanC. albicans cell wall mannanBeta-1,2-manno-oligosaccharides
02

Mechanism of action

Targeting involves neutralization of the cell wall component by monoclonal antibodies to prevent adhesion and promote opsonophagocytosis, or the induction of active immunity through glyconjugate vaccines targeting these specific epitopes.

03

Biological functions

Cell wall structural integrityHost-pathogen interactionImmune system evasionAdhesion to host tissuesPro-inflammatory signaling induction
04

Disease associations

Invasive candidiasisCandidemiaMucosal candidiasisSepsisFungal infection
05

Safety considerations

Potential for cross-reactivity with other fungal speciesVariable expression between different Candida strainsRapid clearance from circulation in diagnostic contextsComplexity of glycan synthesis for vaccine production
06

Interacting drugs

MAb-B6.1 (Experimental monoclonal antibody)

4 more in the full profile.

07

Biomarkers

Platelia Candida Ag (Mannan antigen test)Serum mannan levelsAnti-mannan antibodies

Beyond the preview

Go deeper on Candida albicans beta-1,2-mannan (Beta-mannan).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Candida albicans beta-1,2-mannan (Beta-mannan).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call